Merck and Moderna’s positive Phase 3 INTerpath-001 readout in August 2026 for their personalized mRNA neoantigen vaccine intismeran (mRNA-4157/V940) plus pembrolizumab drove recent sentiment, as the trial met recurrence-free survival and distant metastasis-free survival endpoints in resected high-risk melanoma—the first such success for an individualized mRNA cancer therapy. Companies are now presenting full data at an upcoming medical meeting and engaging regulators on a potential BLA filing, building on sustained five-year Phase 2 benefits showing roughly 49% risk reduction. This positions the mRNA platform ahead of competitors like IO Biotech’s peptide vaccine, which faced FDA pushback on statistical significance, or Replimune’s oncolytic approach with ongoing resubmissions. Traders monitor timelines for manufacturing scale-up, additional trial readouts, and any fast-track or breakthrough designations that could accelerate submission.